Generic Name: lamivudine + tenofovir disoproxil fumarate
Abbreviation: 3TC + TDF
Company: Mylan Pharmaceuticals
Approval Status: Approved
Generic Version Available: No
Cimduo has not yet been reviewed for inclusion in the DHHS list of recommended HIV treatments. Visit https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/0 for the full DHHS guidelines.
Cimduo is an HIV medication. It is in a category of HIV medicines called nucleoside reverse transcriptase inhibitors. Cimduo was approved by the U.S. Food and Drug Administration for the treatment of HIV in February 2018.
Cimduo is a coformulation of two drugs: lamivudine and tenofovir disoproxil fumarate. Both of these drugs can be purchased individually for use in combination with other HIV drugs
Cimduo must be used in combination with other HIV drugs.
Adult Dose: One tablet once a day. Each tablet of Cimduo contains 300 mg lamivudine + 300 mg tenofovir disoproxil fumarate.
Pediatric Dose: One tablet of once a day for those weighing at least 77lbs (35kg). Each tablet of Cimduo contains 300 mg lamivudine + 300 mg tenofovir disoproxil fumarate.
Dosing Info: Take with or without food.
Common side effects among people using Cimduo include: diarrhea, nausea, and dizziness.
Rash is also a common side effect of Cimduo. These rashes usually go away without any change in treatment. In a small number of patients, rash may be serious. If you develop rash, call your doctor as soon as possible.
Cimduo may lead to new or worsening kidney problems, including kidney failure. Your healthcare provider may do blood tests to check your kidneys before and during treatment with Cimduo. If you develop kidney problems, your healthcare provider may need to make changes to your treatment regimen.
Cimduo may lead to new or worsening liver problems. Your healthcare provider may check your liver function before and during treatment with Cimduo. Contact your doctor immediately if you experience yellowing of the skin or eyes, dark-colored-urine, light-colored bowel movements, confusion, weakness or tiredness, loss of appetite, nausea, stomach swelling or pain on the right side of your stomach area.
Cimduo can also cause lactic acidosis, a buildup of lactic acid in the blood. Contact your doctor immediately if you experience nausea, vomiting, or unusual or unexpected stomach discomfort; weakness or tiredness; shortness of breath; weakness in the arms and legs; yellowing of the skin or eyes; or pain in the upper stomach area.
Cimduo may lead to bone problems, including bone pain or bones getting soft or thin, which may lead to fractures. Your healthcare provider may do tests to check your bones.
If you also have hepatitis B virus (HBV) and take Cimduo, your hepatitis may become worse if you stop taking it. Do not stop taking Cimduo without first talking to your healthcare provider.
If you also have hepatitis C virus (HCV) and take Cimduo, your liver disease can worsen if your HCV is being treated with alfa with or without ribavirin. Talk to your health care provider if you have any new symptoms while taking Cimduo and interferon alfa with or without ribavirin.
For a review of drug interactions, including prescription and over-the-counter medications and supplements that should not be taken with Cimduo or may require dose adjustments, consult the Cimduo package insert.
Before taking this medication, tell your doctor if you have kidney disease or liver disease (including hepatitis B). In addition, tell your doctor if you are pregnant or planning to become pregnant, if you are breastfeeding, and all your medical conditions, including all prescription and over-the-counter medications and supplements you are taking.
For More Info: https://aidsinfo.nih.gov/drugs/593/cimduo/0/patient
Last Reviewed: July 20, 2018